A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

被引：4
|
作者：
Shapiro, J. D.
Siu, L. L.
Zalcberg, J. R.
Moore, M. J.
Ringash, J.
Mittmann, N.
Simes, J.
O'Callaghan, C. J.
Tu, D.
Walters, I. B.
Magoski, N.
Smith, P.
Nomikos, D.
Zhu, L.
Savoie, M.
Virk, S.
El-Tahche, F.
Gill, R.
Price, T. J.
Jonker, D. J.
机构：
[1] Cabrini Hosp, Malvern, Australia
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[7] ANZGOG, Camperdown, NSW, Australia
[8] NCIC Clin Trials Grp, Kingston, ON, Canada
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[10] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[11] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[12] Ottawa Hosp, Ottawa, ON, Canada
[13] Univ Ottawa, Ottawa, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS163
引用
收藏
页数：1
相关论文
共 27 条
  • [1] Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial
    Siu, Lillian L.
    Shapiro, Jeremy David
    Jonker, Derek J.
    Karapetis, Christos Stelios
    Zalcberg, John Raymond
    Simes, John
    Couture, Felix
    Moore, Malcolm J.
    Price, Timothy Jay
    Siddiqui, Jehan
    Nott, Louise M.
    Charpentier, Danielle
    Liauw, Winston S.
    Sawyer, Michael B.
    Jefford, Michael
    Magoski, Nadine M.
    Haydon, Andrew Mark
    Walters, Ian B.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO. 20 trial.
    Siu, Lillian L.
    Shapiro, Jeremy D.
    Jonker, Derek J.
    Karapetis, Christos Stelios
    Zalcberg, John Raymond
    Simes, John
    Couture, Felix
    Moore, Malcolm J.
    Price, Timothy Jay
    Siddiqui, Jehan
    Nott, Louise M.
    Charpentier, Danielle
    Liauw, Winston S.
    Sawyer, Michael B.
    Jefford, Michael
    Magoski, Nadine M.
    Haydon, Andrew Mark
    Walters, Ian B.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [3] Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
    Siu, Lillian L.
    Shapiro, Jeremy D.
    Jonker, Derek J.
    Karapetis, Chris S.
    Zalcberg, John R.
    Simes, John
    Couture, Felix
    Moore, Malcolm J.
    Price, Timothy J.
    Siddiqui, Jehan
    Nott, Louise M.
    Charpentier, Danielle
    Liauw, Winston
    Sawyer, Michael B.
    Jefford, Michael
    Magoski, Nadine M.
    Haydon, Andrew
    Walters, Ian
    Ringash, Jolie
    Tu, Dongsheng
    O'Callaghan, Chris J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : 2477 - 2484
  • [4] Quality of life (QoL) assessment in patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or placebo: Results of the NCIC Clinical Trials Group and AGITG CO.20 trial.
    Ringash, Jolie
    Au, Heather-Jane
    Siu, Lillian L.
    Shapiro, Jeremy D.
    Jonker, Derek J.
    Zalcberg, John Raymond
    Moore, Malcolm J.
    Strickland, Andrew H.
    Kotb, Rami
    Jeffery, Mark
    Alcindor, Thierry
    Ng, Siobhan
    Salim, Muhammad
    Sabesan, Sabe S.
    Easaw, Jacob C.
    Shannon, Jennifer Anne
    El-Tahche, Fabyolla
    Walters, Ian B.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [5] Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial (vol 31, pg 2477, 2013)
    Siu, L. L.
    Shapiro, J. D.
    Jonker, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2124 - 2124
  • [6] High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC)
    Jonker, D. J.
    Karapetis, C.
    Harbison, C.
    O'Callaghan, C. J.
    Tu, D.
    Simes, R. J.
    Xu, L.
    Moore, M. J.
    Zalcberg, J. R.
    Khambata-Ford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Maintenance treatment with capecitabine plus cetuximab (CET) for patients with RAS wild-type (wt) advanced colorectal cancer (CRC): A multi-center, phase II clinical trial.
    Yuan, Xianglin
    Liu, Ying
    Yin, Xianli
    Xiong, Jianping
    Zhao, Ben
    Qiu, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care
    Asmis, T. R.
    Powell, E.
    Karapetis, C. S.
    Jonker, D. J.
    Tu, D.
    Jeffery, M.
    Pavlakis, N.
    Gibbs, P.
    Zhu, L.
    Dueck, D. -A.
    Whittom, R.
    Langer, C.
    O'Callaghan, C. J.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 118 - 126
  • [9] Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)-Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)
    Powell, E. D.
    Asmis, T.
    Jonker, D.
    Tu, D.
    Karapetis, C.
    Jeffery, M.
    O'Callaghan, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
    Wasan, Harpreet
    Meade, Angela M.
    Adams, Richard
    Wilson, Richard
    Pugh, Cheryl
    Fisher, David
    Sydes, Benjamin
    Madi, Ayman
    Sizer, Bruce
    Lowdell, Charles
    Middleton, Gary
    Butler, Rachel
    Kaplan, Richard
    Maughan, Tim
    LANCET ONCOLOGY, 2014, 15 (06): : 631 - 639
123